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Aims: To analyze the clinical relevance of O6-methylguanine-
DNA methyltransferase in rectal adenocarcinoma treated with 
chemoradiotherapy followed by surgery.
Methods: Tissue samples from 29 rectal adenocarcinoma patients 
were obtained after chemoradiotherapy. O6-methylguanine-DNA 
methyltransferase promoter methylation status was established by 
methylation-specific polymerase chain reaction. O6-methylguanine-
DNA methyltransferase protein levels were determined by 
immunohistochemistry. Clinicopathologic variables, including 
treatment regression grade, recurrence, lymph node invasion, and 
stage and differentiation grade of the tumor, were determined.
Results: The O6-methylguanine-DNA methyltransferase gene 
promoter was methylated in 81.5% of samples. Most patients (88.9%) 
showed low O6-methylguanine-DNA methyltransferase protein 
expression. O6-methylguanine-DNA methyltransferase methylation 
status was not correlated with any of the clinicopathological variables 
determined in rectal adenocarcinomas selected for chemoradiotherapy.
Conclusion: O6-methylguanine-DNA methyltransferase methylation 
status is not correlated with clinicopathologic variables examined in 
rectal adenocarcinoma selected for chemoradiotherapy, although its 
role as a biomarker awaits further investigation.
Keywords: Chemoradiotherapy, O6-methylguanine-DNA 
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Patients with rectal adenocarcinoma stage II-III are usually treated 
with preoperative chemoradiotherapy based on 5-fluorouracil 
or capecitabine. However, little data on molecular biomarkers 
for the prognosis and treatment response in colorectal cancer 
has been obtained (1). The enzyme O6-methylguanine-DNA 
methyltransferase (MGMT), which eliminates methyl groups in 
the O6-guanine position avoiding G:C to A:T transitions, has also 
been related to colorectal cancer (2,3). MGMT prevents cell death 
due to cytotoxic drugs by repairing DNA, but it can be silenced 
by epigenetic methylation (4). Loss of MGMT expression has 
been detected in colorectal cancer and associated with G to A 
transition in the p53, K-ras, and PIK3CA genes (5). Previous studies 
suggested that MGMT promoter methylation status was related to 
glioblastoma treatment failure (6). In this study, MGMT expression 
and MGMT promoter methylation status were evaluated in rectal 
adenocarcinoma patients after chemoradiotherapy treatment in order 
to determine their status and relevance as prognostic biomarkers.
MATERIALS AND METHODS
Clinical history and tissue samples
Twenty-nine rectal adenocarcinoma patients (stage II-III) who 
were candidates for preoperative chemoradiotherapy were recruited 
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after they gave informed consent (Biomedical Investigation 
Ethic Committee; Servicio Andaluz de Salud). All patients 
were evaluated before treatment (physical examination with a 
digital rectal examination, colonoscopy and biopsy, chest X-ray, 
abdominopelvic scan and/or endorectal ultrasound, and magnetic 
resonance image of the pelvis). These patients were treated with 
pelvic radiotherapy (46-50 Gy in 2 Gy fractions) and intravenous 
5-fluorouracil (5-day cycles of 500 mg/m2 5-fluorouracil every 21 
days) or capecitabine (4 cycles of 1250 mg/m2 capecitabine every 
12 h for 14 days) followed by surgery (total mesorectal excision) 6 
weeks after chemoradiotherapy. Tumor samples were obtained from 
each patient from endoscopic biopsy before chemoradiotherapy. 
The chemoradiotherapy response was staged histopathologically on 
the basis of tumor regression grade (Mandard’s classification: grade 
I and II = complete/partial regression and grade III, IV, or V = no 
regression) (7). Two expert pathologists evaluated an intra-operative 
sample after chemoradiotherapy. Demographic data (sex and age) 
were obtained. In addition, clinicopathological variables, including 
tumor differentiation grade, tumor stage, treatment regression 
grade, recurrence, and lymph node invasion, were analyzed.
Methylation-specific polymerase chain reaction and 
immunohistochemistry
DNA was extracted from paraffin-embedded tissues by using 
a Chemagic MSM I robot (Chemagen, Germany, Baesweiler). 
Methylation patterns in CpG islands of the MGMT promoter 
were determined by methylation-specific polymerase chain 
reaction as previously described (8). Samples were classified as 
methylated (amplification product with M or both M and UM 
primers) and unmethylated (amplification with UM primers 
only). Immunohistochemical analysis was performed with a Dako 
Autostainer EnVision™ FLEX System kit (Agilent Technologies) 
and the results evaluated by two experienced pathologists. MGMT 
(1:50, Santa Cruz Biotechnology, Inc., Heidelberg, Germany) mAb 
was used as the label and 3.3'-diaminobenzidine as the chromogen 
substrate. Counterstaining was performed with hematoxylin (blue). 
As previously described by Oliver et al. (2), MGMT staining were 
scored and grouped as low (<50%) and high expression (≥50%).
Statistical analysis
SPSS version 15.0 (IBM, Chicago, IL) was used for data analyses. 
Associations between promoter gene methylation status and 
clinicopathologic variables were analyzed by Fisher’s exact test. 
Results were considered statistically significant if p<0.05.
RESULTS
The clinical patient characteristics are summarized in Table 1. 
The mean age was 64.43±12.24 years (range, 33-83 years); 75.9% 
(22/29) of patients were male and 24.1% (7/29) were female. The 
median follow-up period was 20.53±9.07 months. No patient 
died due to rectal cancer, and disease recurrence was observed 
in 13.8% (4/29). MGMT promoter methylation status could be 
determined in 93.1% of specimens (27/29). Of the 27 patients, the 
MGMT gene promoter was methylated 81.5% (22/27) (Figure 1). 
Immunohistochemical analysis (Figure 2) showed low MGMT 
protein expression in most patients (88.9%). Only 11.1% of 
patients showed high expression of MGMT. We also examined 
the association between MGMT promoter methylation and 
clinicopathologic features. MGMT promoter methylation status 
was not associated with sex, tumor differentiation, or tumor stage. 
Furthermore, no association between MGMT methylation and the 
clinicopathologic variables examined was detected (Table 2).
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TABLE 1. Characteristics of rectal cancer patients
All patients (n=29)
Sex
Male 22 (75.9%) 
Female 7 (24.1%)
Age
≥50 years 27 (93.1%)
<50 years 2 (6.9%)












FIG. 1. Methylation-specific polymerase chain reaction analysis of the O6-methylguanine-
DNA methyltransferase promoter in rectal adenocarcinoma tissue samples. DNA was 
extracted by using a Chemagic MSM I robot (Chemagen, Germany, Baesweiler), denatured, 
and purified with an EpiTect Bisulfite kit (Qiagen, USA, Maryland). Primer sequences 
for the unmethylated reaction were 5`-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3` 
(forward primer) and 5`-AACTCCACACTCTTCCAAAAACAAAACA-3` (reverse primer) 
and for the methylated reaction were 5`-TTTCGACGTTCTAGGTTTTCGC-3` (forward 
primer) and 5`-GCACTCTTCCGAAAACGAAACG-3` (reverse primer). Polymerase chain 
reaction-amplified products were electrophoresed on 3% agarose gels, visualized by staining 
with ethidium bromide, and examined under ultraviolet illumination. The representative 
image depicts O6-methylguanine-DNA methyltransferase promoter methylation analysis of 
18 samples. Patients with methylated promoters showed amplification in both unmethylated 
and methylated lanes or the methylated lane alone. The lack of a band in the lane 
corresponding to methylation-specific primers for rectal cancer sample 2, 6 or 18 reflects 
the absence of O6-methylguanine-DNA methyltransferase promoter methylation.
M: methylated; UM: unmethylated
DISCUSSION
The relationship between MGMT and colorectal cancer remains 
unclear, and results have been contradictory. Whereas Nilsson et 
al. (9) found a lower risk of recurrence in 5-fluorouracil-treated 
colorectal cancer patients with a methylated versus unmethylated 
MGMT promoter, Shima et al. (3) concluded that neither MGMT 
promoter methylation nor loss of MGMT expression is a useful 
prognostic biomarker. Sinha et al. (10) observed that MGMT 
methylation was associated with stage III in sporadic colorectal 
cancer cases. Recently, the methylation status of MGMT has been 
correlated with pathologic complete response in colorectal cancer 
patients (11).
Shalaby et al. (12) showed a good correlation between MGMT 
methylation and downregulation of its mRNA expression. Although 
these authors proposed MGMT methylation as a new biomarker 
to differentiate benign and malignant rectal tumors, no relation 
between MGMT methylation and clinicopathological features was 
detected. Sun et al. (13) showed that even the MGMT promoter 
methylation status of plasma-cell-free DNA was associated with 
a better tumor response. In addition, MGMT methylation levels in 
the blood were similar to those in rectal cancer tissues (12). Our 
results showed that the methylation status of the MGMT promoter 
was not associated with a better treatment response. However, the 
role of MGMT promoter methylation status as an early biomarker 
of colorectal cancer has not yet been established, despite several 
studies in colorectal adenoma and adenocarcinoma (14,15). In fact, 
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TABLE 2. Correlation between MGMT methylation status and demographic and 
clinicopathologic variables
Variables




Male 3 (11.1) 17 (63)
Female 2 (7.4) 5 (18.5)
Tumor differentiation grade
Well-moderately 4 (14.8) 21 (77.8)
Poorly 1 (3.8) 1 (3.8)
Tumor stage
II 1 (3.8) 9 (33.3)
III 4 (14.8) 13 (48.1)
Recurrence
Yes 3 (11.1) 20 (74)
No 2 (7.4) 2 (7.4)
Treatment regression grade
I, II 1 (3.7) 9 (33.3)
III, IV, V 4 (14.8) 13 (48.1)
Lymph node metastasis
Yes 4 (14.8) 13 (48.1)
No 1 (3.8) 9 (33.3)
MGMT: O6-methylguanine-DNA methyltransferase
FIG. 2. a-c. Immunohistochemical staining of rectal adenocarcinoma tissue samples with 
a mouse monoclonal antibody against human O6-methylguanine-DNA methyltransferase 
protein. Formalin-fixed, paraffin-embedded rectal cancer samples were stained with 
an antibody against O6-methylguanine-DNA methyltransferase (see Methods). O6-
methylguanine-DNA methyltransferase staining of tumor cells was scored and grouped as 
low expression (<50%) (-, +, and ++ scores) and high expression (≥50%) (+++ and ++++ 
scores). The intensity of O6-methylguanine-DNA methyltransferase staining was scored 
as low or high. The figure shows representative photomicrographs of slides illustrating 
different percentages of O6-methylguanine-DNA methyltransferase expression. A tumor 
with no detectable O6-methylguanine-DNA methyltransferase expression (a); A positive 
tumor with low O6-methylguanine-DNA methyltransferase expression (˂50%) (b); A 
positive tumor with high O6-methylguanine-DNA methyltransferase expression (>50%) 
(20× magnification) (c).
Sideris et al. (16) showed recently that there was no association 
between the status of MGMT expression and pathological features, 
including response to neo-adjuvant therapy. Future research will be 
needed to elucidate the relationship between these biomarkers and 
rectal cancer treatment. 
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